JERUSALEM, July 19, 2017 /PRNewswire/ --
Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical-stage
biopharmaceutical company focused on developing drugs based on its
proprietary Accordion Pill[TM]
platform technology, announces that the Patent Registry
Intellectual Property Department of Hong Kong has issued a
Certificate of Grant of a Hong
Kong patent for an Accordion Pill containing certain drugs,
including the combination of Carbidopa and Levodopa. The patent,
granted under No. HK1158545, is titled "Carbidopa/Levodopa
Gastroretentive Drug Delivery" and is currently scheduled to remain
in force until April 2029. The patent
belongs to the Company's IN-7 patent family, which already includes
patents granted in the U.S., Europe, China, Japan,
South Korea, South Africa and Israel.
"We remain committed to building out our IN-7 patent family in
order to fortify our global leadership in gastric retention drug
delivery with the Accordion Pill technology platform and this
patent further strengthens that position," stated Jeffrey A. Meckler, Chief Executive Officer of
Intec Pharma. "This Hong Kong patent secures key elements of our
Accordion Pill technology platform and our leading product, the
Accordion Pill Carbidopa/Levodopa (AP-CD/LD), in significant
markets. The AP-CD/LD is currently in a global Phase III clinical
trial in advanced Parkinson's disease and the expanded patent
protection will enhance any global commercial efforts for
AP-CDLD."
About Intec Pharma Ltd.
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company
focused on developing drugs based on its proprietary Accordion Pill
platform technology. The Company's Accordion Pill is an oral drug
delivery system that is designed to improve the efficacy and safety
of existing drugs and drugs in development by utilizing an
efficient gastric retention and specific release mechanism. The
Company's product pipeline includes two product candidates in
clinical trial stages: Accordion Pill Carbidopa/Levodopa, or
AP-CD/LD, which is being developed for the treatment of Parkinson's
disease symptoms in advanced Parkinson's disease patients and
AP-CBD/THC, an Accordion Pill with the two primary cannabinoids
contained in Cannabis sativa, cannabidiol (CBD) and
tetrahydrocannabinol (THC), which is being developed for various
indications including low back neuropathic pain and
fibromyalgia.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company's control.
Important factors that could cause actual results, developments and
business decisions to differ materially from forward-looking
statements are described in the sections titled "Risk Factors" in
the company's filings with the Securities and Exchange Commission,
and include the following: the company's ability to develop and
commercialize its product candidates and obtain additional
financing necessary therefor; the length, cost and uncertain
results of the company's clinical trials; including uncertainty
regarding the Company's ability to enroll the required number of
patients therein; the potential of adverse side effects, other
safety risks, or legal prohibitions on the use of certain products
in certain jurisdictions that could preclude the approval of the
company's drug candidates; the availability of reimbursement from
government authorities and health insurance companies for the
company's products; the impact of product liability lawsuits; and
the influence of extensive and costly government regulation.
Contacts:
Jeffrey A. Meckler
Chief Executive Officer
Intec Pharma
jeffrey@intecpharma.com
Anne Marie Fields
Senior Vice President
LHA
212-838-3777
afields@lhai.com
SOURCE Intec Pharma Ltd.